NOVT Q1 2026: Bookings Surge 37% as GenAI and Medical Consumables Fuel Multi-Segment Upside
Novanta’s Q1 marked an inflection in both demand and execution, with bookings up sharply and broad-based segment growth driven by GenAI infrastructure and medical consumables tailwinds. Management raised revenue guidance and signaled accelerating momentum into the second half, while cost volatility from tariffs and freight remains a near-term margin watchpoint. Investors should focus on execution in repricing actions and the ramp of new product pipelines as the company leans into secular growth markets.
Summary
- GenAI and Medical Momentum: GenAI infrastructure and medical consumables drove robust bookings and diversified growth.
- Margin Rebuild Underway: Tariff and freight shocks pressured Q1 margins but repricing and cost actions are set to recover profitability.
- Acquisition Capacity and Pipeline: Strong balance sheet and active M&A pipeline position Novanta for further portfolio expansion in 2026.
Business Overview
Novanta is a precision technology manufacturer supplying proprietary subsystems and components for medical solutions (advanced surgery, precision medicine) and automation-enabling technologies (robotics, automation, precision manufacturing). The company generates revenue by selling highly engineered products to OEMs, with sticky, design-in relationships that often last a decade. Its business is split roughly evenly between medical (53% of Q1 sales) and advanced industrial markets (47%), with medical consumables, surgical systems, robotics, and GenAI-driven industrial applications as key growth engines.
Performance Analysis
Q1 2026 delivered a step-change in demand signals: Bookings surged 37% year-over-year, with every business line posting double-digit bookings and revenue growth. The book-to-bill ratio of 1.1 and a rising backlog provide strong forward visibility. Segmentally, automation-enabling technology revenue grew 7% and medical solutions 15%, both outpacing expectations. New product sales, a key vitality metric, rose over 50% and now comprise 27% of total sales, underscoring the success of recent innovation cycles.
Margin dynamics were mixed: Adjusted EBITDA climbed 14% and margin expanded 70 basis points, but gross margin slipped 60 basis points YoY due to a rapid spike in tariffs and freight costs, outpacing Novanta’s ability to reprice. The company responded with immediate surcharges and price hikes, with benefits expected to flow through in Q3 and beyond. Cash flow was a standout, with operating cash flow up 63% YoY and conversion exceeding 200% of net income, reflecting strong collections and inventory investments to secure supply for growth.
- Bookings Acceleration: All segments posted double-digit bookings gains, with robotics and automation bookings up 50% YoY.
- GenAI Infrastructure Exposure: GenAI-related applications represented 15% of Q1 revenue, growing 20% YoY, with further acceleration expected.
- Medical Consumables Engine: Medical consumables now contribute 15% of revenue, sustaining double-digit growth and expanding Novanta’s recurring revenue base.
Segment momentum is broad-based, with advanced surgery, robotics, and precision manufacturing all delivering sequential and YoY growth, and design wins up nearly 30%. The company’s mix of innovation-driven sales and diversified end markets underpins confidence in the raised full-year outlook.
Executive Commentary
"Bookings grew 37% year-over-year, with a book-to-bill of 1.10 on continued new product momentum and strong commercial executions. Every business delivered double-digit bookings growth and year-over-year revenue growth. Profit performance was equally strong."
Matthias Glastra, Chair and Chief Executive Officer
"Operating cash flow in the first quarter was $52 million compared to $32 million in the prior year, representing 63% growth year-over-year and a six-fold increase sequentially from the week fourth quarter. This represents over 200% cash flow conversion of net income."
Robert Buckley, Chief Financial Officer
Strategic Positioning
1. GenAI Infrastructure and Advanced Industrial Tailwinds
GenAI-driven demand is now a material lever, with 15% of Q1 revenue tied to applications like EUV/DUV lithography, GPU drilling, and probe card production. Novanta’s proprietary subsystems for laser beam steering and high-precision motion are uniquely positioned for these advanced manufacturing needs, and management expects this exposure to accelerate as the year progresses.
2. Medical Consumables and Advanced Surgery Expansion
The medical consumables franchise, at 15% of revenue, is scaling as a high-growth, recurring revenue engine. Advanced surgery, driven by next-generation insufflators and new product launches, posted double-digit growth, with strong OEM adoption and continued new product ramps.
3. Innovation and Design Win Vitality
New product revenue jumped 50%, and the vitality index reached 27%, reflecting a robust pipeline and successful commercialization. Design wins, up nearly 30%, signal sustained future revenue streams and deeper customer integration.
4. Manufacturing Footprint Transformation
Facility consolidation and regionalization are underway, with two site closures on track for Q2. These moves are expected to unlock gross margin gains and operational resilience, supporting in-region supply and preferred supplier status with OEMs.
5. Acquisition Pipeline and Capital Deployment
Novanta’s net cash position and negative net leverage (-0.6x) enable aggressive pursuit of M&A in medical technologies, consumables, and embedded software. The pipeline is active, with management prioritizing deals that enhance growth, reduce cyclicality, and fit disciplined return thresholds.
Key Considerations
This quarter highlights Novanta’s ability to capitalize on secular growth markets while actively managing acute cost headwinds. The interplay of innovation, operational discipline, and capital allocation will determine the durability of this momentum through 2026.
Key Considerations:
- Tariff and Freight Volatility: Rapidly changing tariffs and logistics costs pressured Q1 gross margins, but repricing and surcharges are being implemented to recover profitability in H2.
- Backlog and Bookings Visibility: Record bookings and a 1.1 book-to-bill ratio provide strong forward visibility, supporting the raised revenue outlook.
- Innovation-Driven Growth: New product launches and design wins are translating into higher vitality and embedded future sales, especially in GenAI and medical markets.
- Acquisition-Driven Optionality: Ample balance sheet capacity and an active M&A pipeline position Novanta to further expand and diversify its portfolio in 2026.
Risks
Macro and geopolitical uncertainty, especially around tariffs and input costs, remains a material risk to near-term margins and supply chain stability. The company’s ability to execute on repricing and cost actions, as well as to close and integrate acquisitions without disruption, will be critical. Any slowdown in GenAI infrastructure buildout or delays in medical product ramps could temper the current growth trajectory.
Forward Outlook
For Q2 2026, Novanta guided to:
- GAAP revenue of $259 million to $264 million (6% to 8% organic growth)
- Adjusted EBITDA of $58 million to $62 million (margin up over 100 bps YoY)
- Diluted EPS of $0.81 to $0.86 (6% to 13% YoY growth)
For full-year 2026, management raised revenue guidance to $1,040 million to $1,055 million (reported growth over 7%, organic up to 6%) and reaffirmed adjusted EBITDA ($245 million to $250 million) and EPS ($3.50 to $3.65) targets.
Management highlighted:
- Strong bookings visibility and new product ramps underpinning confidence in the outlook
- Margin recovery expected in H2 as price/cost actions and site consolidations take full effect
Takeaways
Novanta’s Q1 results underscore its ability to capture secular growth in GenAI and medical consumables, while actively navigating cost volatility and supply chain complexity.
- Bookings and Backlog Strength: Robust bookings growth and a rising backlog set the stage for sustained top-line momentum into H2 2026.
- Margin Recovery Path: Near-term margin pressure from tariffs is being addressed through repricing, surcharges, and manufacturing consolidation, with improvement expected from Q3 onward.
- Execution Watchpoints: Investors should monitor progress in repricing actions, new product commercialization, and the pace of M&A as key levers for upside or risk in the coming quarters.
Conclusion
Novanta’s Q1 marks a decisive turn upward, with demand signals and innovation-driven growth translating into a raised outlook and strong operational execution. The company’s ability to manage cost volatility and deliver on its innovation and acquisition agenda will be pivotal for sustaining its upward trajectory through 2026.
Industry Read-Through
Novanta’s results signal broad-based strength in GenAI-related capital equipment, medical consumables, and advanced manufacturing subsystems, reflecting secular tailwinds for suppliers with proprietary, design-in technologies. The sharp rebound in bookings and new product revenue is a positive read-through for OEMs and component suppliers serving AI data center, semiconductor, and minimally invasive surgery markets. However, the acute impact of tariffs and freight highlights ongoing cost volatility for global manufacturers, reinforcing the need for agile pricing and regionalized supply chains across the industry.